Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PTGX - Protagonist Therapeutics, Inc

IEX Last Trade
39.02
0.160   0.410%

Share volume: 10,190
Last Updated: Fri 27 Dec 2024 08:30:20 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$38.86
0.16
0.41%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 9%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.68%
1 Month
-12.10%
3 Months
-11.33%
6 Months
23.93%
1 Year
68.56%
2 Year
291.19%
Key data
Stock price
$39.02
P/E Ratio 
0.00
DAY RANGE
$38.50 - $39.66
EPS 
$0.00
52 WEEK RANGE
$22.79 - $48.89
52 WEEK CHANGE
$72.31
MARKET CAP 
2.526 B
YIELD 
N/A
SHARES OUTSTANDING 
58.905 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.25
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$827,439
AVERAGE 30 VOLUME 
$676,905
Company detail
CEO: Dinesh V. Patel
Region: US
Website: protagonist-inc.com
Employees: 120
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.

Recent news